Introduction {#sec1-1}
============

Stroke is the major leading cause of long-term disability and mortality worldwide. It has accounted for nearly 5.7 million deaths worldwide, and 87% of these deaths occur in low and middle-income countries.\[[@ref1]\] The incidence of stroke in South Asian countries has increased by \>100%, whereas this is decreased by 42% in developed European countries in the past four decades.\[[@ref2]\] Ischemic stroke (IS) accounts for 85% of overall stroke, and its pathophysiology is regulated by a combination of lifestyle, environmental, and unclear genetic risk factors.\[[@ref3]\] The pathogenesis of stroke is based on atherosclerosis, which can be reviewed as an inflammatory process. Inflammation and genetics are both prominent mechanisms in the pathogenesis of IS.\[[@ref4]\] Numerous recent studies have focused on the inflammatory reactions after stroke and identifying the roles of important inflammatory signaling molecules, mainly cytokines.\[[@ref5][@ref6][@ref7][@ref8]\] Cytokines are up-regulated in the brain after stroke and are expressed not only in immunological cells but also in glial cells and neurons.\[[@ref9]\] However, the mechanisms leading to increased release of inflammatory cytokines in patients with stroke remain unclear. Recent advances in genetic epidemiology have revealed that genetic variants increase the risk of IS including polymorphisms in inflammatory cytokine genes.

Transforming growth factor-beta (TGF-β) is a prototype of a large family of cytokines and in mammals; TGF-β has been shown to have three isoforms (TGFβ-1, 2, and 3) with very similar biological properties. TGF-β1 has been observed to inhibit the proliferation and migration of vascular smooth muscle cells in culture.\[[@ref10][@ref11]\] TGF-β1 is a multifunctional pleiotropic cytokine produced in particular by astrocytes and microglia in response to brain injury.\[[@ref12][@ref13]\] It plays an important role in inflammatory inhibition, immune regulation, cell apoptosis, lipid metabolism, hypertension, and atherosclerotic plaque formation and its levels are mainly determined by genetic factors under physiological condition.\[[@ref14][@ref15][@ref16]\] Most specifically after a stroke, it reduces glial activation, decreases the expression and efficacy of other cytokines, suppresses the release of harmful oxygen and nitrogen derived products, promotes angiogenesis in the penumbra area, causes less brain edema with less neutrophil adherence to endothelial cells, and stimulates the release of interleukin-1 receptor antagonist.\[[@ref17][@ref18]\]

The human TGF-β1 gene is mapped on chromosome 19q13.2, full length of 23.56 kB, includes seven exons and six introns with multiple polymorphism loci, more than 147 single nucleotide polymorphism (SNP) sites that have been known.\[[@ref19]\] Shah *et al*. analyzed the regulating region of TGF-β1 gene and found 10 SNPs initially except the common mutation of G800A (rs1800468), C509T (rs1800469), and T869C (rs1800470; Leu10/Pro10; T29-\>C), which presents that the regulating region was large span and rich in polymorphisms that could affect on the progression, development, and prognosis of TGF-β1 related disease by means of influencing the transcription and expression of TGF-β1.\[[@ref20]\] The G800A and C509T polymorphisms are located in the promoter region; their precise effect is still unknown, but due to their location, they are considered possible modulators of the expression of TGF-β. T869C gene polymorphism has been indicated to be associated with elevated TGF-β gene and levels.\[[@ref16][@ref21]\] T869C polymorphism is located in the signal peptide sequence; this sequence is involved in the export of synthesized protein across the membranes of the endoplasmic reticulum and is located at potentially important positions that influence the activation of TGF-β protein.\[[@ref22]\]

Till date, a few studies have been published on the association between TGF-β1 polymorphisms\[[@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29]\] and risk of IS with one SNP and only two studies have examined the TGF-β1 haplotype.\[[@ref23][@ref27]\] The study by Peng *et al*.\[[@ref23]\] suggested that C-509T and T869C gene polymorphisms in TGF-β1 might be a critical risk factor for genetic susceptibility to confidence interval (CI) and the study by Tao *et al*.\[[@ref27]\] suggested that haplotypes in the TGF-β1 gene might be genetic markers for cerebral infarction in the Chinese population. Although a previously published meta-analysis of six studies by Peng *et al*.\[[@ref30]\] found no significant association between T869C gene polymorphism of TGF-β1 and risk of IS. Due to conflicting results from the previously published literature, well-designed prospective were warranted to reach a definitive conclusion. To the best of our knowledge, most of the studies have been conducted in an Asian population, whereas no study has been conducted in Indian population so far. Due to large variations in the ethnic and genetic background between the Asian and Indian population, the results from the Asian studies cannot be used to ascertain the risk of these polymorphisms in Indian settings. Therefore, we conducted this case--control study to investigate the association of the TGF-β1 gene (C509T, G800A, and T869C) polymorphisms, and their haplotypes with the risk of IS in North Indian population.

Methods {#sec1-2}
=======

Subjects {#sec2-1}
--------

The study was conducted in the Department of Neurology, All India Institute of Medical Sciences, New Delhi in collaboration with Institute of Genomics and Integrative Biology, New Delhi. The study was a hospital-based case--control study and was completed in 1½ years (October 2013 to April 2015). Patients with a history of transient ischemic attack, fever, rheumatologic disease, autoimmune disease, any acute or chronic infection, computed tomography (CT) or magnetic resonance imaging (MRI) proven hemorrhagic stroke, and a history of regular immunosuppressive or analgesic therapies were excluded from the study. Patients were recruited after radiologic confirmation of IS by CT or MRI scans of the brain. All patients had clinical signs consistent with the World Health Organization definition of stroke. Control subjects with age- and sex-matched individuals was recruited from volunteers and healthy persons accompanying the patients in the general outpatient department (OPD) and was assessed by questionnaire for verifying stroke-free status (QVSFS). Written informed consent was obtained from all subjects before the collection of information and blood samples. The study was approved by the Local Institutional Ethics Committee. Inclusion and exclusion criteria for cases and controls are listed below:

Inclusion criteria for cases {#sec2-2}
----------------------------

Age 18--85 years (both sexes)Diagnosis of stroke as defined by the World Health OrganizationNoncontrast computed tomography head/MRI consistent with ischemic or intracerebral hemorrhageStroke onset within 3 years before the recruitmentShould be Resident of North India (residing for the last 1 year or longer).

Exclusion criteria for cases {#sec2-3}
----------------------------

Unwillingness to provide written informed consent (by self or legally authorized representative \[LAR\])Stroke associated with pregnancyStroke associated with surgery.

Inclusion criteria for controls {#sec2-4}
-------------------------------

Age 18--85 years (both sexes)Age (±5 years) and sex matchedControls have not had prior stroke assessed by QVSFSSpouse or friends but not a relative (by blood)Should be Resident of North India (residing for the last 1 year or longer)No evidence of any serious brain disorders.

Exclusion criteria for controls {#sec2-5}
-------------------------------

Unwillingness to provide written informed consent (by self or LAR)PregnancySubjects with any serious brain disorder.

Sample size {#sec2-6}
-----------

The sample size was calculated using software StatsDirect (StatsDirect Ltd.). Sample size calculation was based on our primary hypothesis that there is an association between TGF-β1 (C509T, G800A, and T869C) gene polymorphisms and risk of IS. We took parameters of published article by Peng *et al*.\[[@ref23]\] in which probability of exposure in controls was 0.35 and in cases was 0.5. Taking into an account, controls per case subject = 1, alpha = 0.05/3 = 0.017, power = 0.8. The estimated minimum sample size (cases required) =239. The final sample size of 250 cases and 250 controls were taken considering any sample loss.

Clinical examination {#sec2-7}
--------------------

A detailed history of hypertension, diabetes, stroke, dyslipidemia, alcohol intake, smoking, myocardial infarction, atrial fibrillation, migraine, asthma, clinical investigation, including lipid profile, blood chemistry, and severity of stroke using National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel index (BI) were carried out. IS was categorized using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification.\[[@ref31]\] TOAST defines small-vessel disease only if the subcortical lesions are smaller than 15 mm and large artery atherosclerosis only if there is stenosis (\>50%) in the corresponding artery. Therefore, subcortical infarction of \>15 mm in size and infarctions with a vulnerable plaque with stenosis \<50% should be classified as stroke of undetermined etiology.\[[@ref31]\] At 6 months, disability and functional independence were assessed telephonically by mRS and BI scales.

Definition of variables {#sec2-8}
-----------------------

Definitions of variables were adapted from our published study protocol\[[@ref32]\] and are as follows: Hypertension: Subjects will be considered to have hypertension if they either have the diagnosis of hypertension or treated for hypertension before the stroke or reference date. Diabetes: If a subject will have the diagnosis documented by a physician in the medical record or if fasting blood sugar level will be \>126 mg/dl. Dyslipidemia: If they either have the diagnosis of dyslipidemia or treated for dyslipidemia. Smoker: person will be defined as regular smokers if a person smoking ≥1 cigarettes daily, Bidis and cigar for proceeding \>3 months.

Genotype determination {#sec2-9}
----------------------

Four milliliters of venous blood samples was taken from IS patients and controls in a tube containing ethylene diamine tetraacetic acid. Genomic deoxyribose nucleic acid (DNA) was isolated from whole blood through standard phenol-chloroform method. The primers were designed for the selected SNPs using the Primer3 online tool, (<http://www.bioinfo.ut.ee/primer3-0.4.0/>). Primers were obtained from Imperial Life Sciences (P) Limited; Haryana, India. TGF-β1 regions were amplified using the primer sequences and conditions for polymerase chain reaction (PCR) listed in [Table 1](#T1){ref-type="table"} and were carried out in T-100 thermal cycler (Bio-Rad, Gurgaon, and Haryana, India). The PCR amplification was performed in a total volume of 10 μl mixture containing: 1 μl (50 ng) genomic DNA, 1 μl ×10 buffer solution, 0.1 μl 2.5 U Taq DNA polymerase ((Bangalore Genei, Bangalore, India), 0.2 μl (20 pmol) of each primer, and 0.2 μl (200 μmol/l) of each deoxynucleotide triphosphate. Genotyping was performed through the SNaPshot method on 3130xl automated DNA sequencer (Applied Biosystems, USA).

###### 

List of primer sequences and polymerase chain reaction conditions used for transforming growth factor-β1 gene polymorphisms

![](AIAN-20-5-g001)

Statistical analysis {#sec2-10}
--------------------

Conditional logistic regression analysis was used to estimate the strength of association between TGF-β1 gene polymorphisms with risk of IS using odds ratio (OR) and 95% confidence interval (CI). Multivariate logistic regression analysis was used to manage the confounding effects of demographic and risk factor variables associated with IS. *P* \< 0.05 was considered statistically significant. Data were analyzed using the STATA, version 13.0 (StataCorp LP, StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX, USA). Haplotypes were reconstructed by PHASE 2.0 and patterns of linkage disequilibrium (LD) were analyzed using HaploView 4.2 software.\[[@ref33]\] The threshold value of the frequencies of the haplotypes included in the analysis was set to 2%. All the haplotypes below the threshold value were excluded from the analysis.

Results {#sec1-3}
=======

After screening 389 stroke cases, 250 IS cases were included in the study. For the control group, 321 people were screened, and 250 age- and sex-matched controls were recruited for the study. The mean age of IS patients was 52.8 ± 12.5 years and control group was 50.9 ± 12.7 years, and both groups included 203 males and 47 females. The clinical, demographic, and risk factor characteristics of IS patients and controls are presented in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. The risk factors examined such as history of hypertension (cases 58.4% vs. controls 16.8%), diabetes (cases 31.6% vs. controls 10.4%), smoking (cases 38.8% vs. controls 26.8%), alcohol intake (cases 32.4% vs. controls 22.4%), and dyslipidemia (cases 22.8% vs. controls 5.6%) were found significantly more often in cases than in controls (*P* \< 0.05).

###### 

Characteristics of ischemic stroke patients and controls
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###### 

Demographic and risk factors details in ischemic stroke cases and control subjects

![](AIAN-20-5-g003)

Of 250 cases, 157 (62.8%) cases were recruited from the OPD, and 93 (37.2%) cases were recruited from the inpatient department. 240 cases (96.0%) completed full 6 months telephonic follow-up, seven patients (2.8%) died, two patients (0.4%) had a recurrence of IS, and 10 (4.0%) were lost to follow-up. The mean and standard deviation (SD) was 12.55 ± 13.42 for the NIHSS at admission, 3.06 ± 1.05 for mRS and 63.56 ± 16.69 for BI at discharge. After a telephonic follow-up at 6 months, the mean and SD was 1.30 ± 1.16 for mRS and 85.31 ± 15.26 for BI.

All genotypes and allelic frequencies were in accordance to Hardy-Weinberg Equilibrium (HWE) in both IS cases and control subjects. Genetic analysis of TGF-β1 (C509T, G800A, and T869C) gene polymorphisms was conducted for all 250 IS cases and 250 controls and are summarized in [Table 4](#T4){ref-type="table"}. Adjusted conditional logistic regression analysis showed a significant association of C509T (OR, 2.1; 95% CI; 1.2--3.8), G800A (OR, 4.4; 95% CI; 2.1--9.3), and T869C (OR, 2.6; 95% CI; 1.5--4.5) polymorphisms of TGF-β1 gene with the risk of IS under dominant model.

###### 

Allelic and genotypic frequencies of Transforming growth factor-β1 (C509T, G800A, and T869C) gene polymorphisms in ischemic stroke cases and controls
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Stratification analysis based on TOAST classification, we observed a significant association between TGF-β1 C509T gene polymorphism and risk of IS under dominant and allelic models for large vessel disease (LVD), small vessel disease (SVD), and cardioembolic (CE) except for others (stroke due to determined and undetermined etiology) subtype of IS. For TGF-β1 G800A gene polymorphism, a significant association with the risk of IS was observed for all subtypes of IS under dominant and allelic models. For TGF-β1 T869C gene polymorphism, a significant association with the risk of IS was observed for LVD, SVD, others (Stroke due to determined and undetermined etiology) except for CE subtype of IS under dominant and allelic models.

The haplotype frequency distribution of the TGF-β1 and its association with IS are represented in [Table 5](#T5){ref-type="table"}. Among all combinations of haplotypes, C509-A800-T869 and T509-G800-C869 haplotypes were found to be significantly associated with the increased risk of IS. Strong LD (D\' = 0.51, *r*^2^ = 0.23) was identified between two SNPs (C509T and T869C) of the TGF-β1 gene \[[Figure 1](#F1){ref-type="fig"}\].

###### 

Frequencies and association of transforming growth factor-β1 (C509T, G800A, and T869C) haplotypes in ischemic stroke cases and controls
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![Linkage disequilibrium plots of the three single nucleotide polymorphisms (C509T, G800A, and T869C) of transforming growth factor-beta 1 gene in North Indian population. The figures in the squares are the pair-wise calculations of (a) *r*^2^ or (b) D\'. The squares with the "0" indicate *r*^2^ = 0 (i.e., No linkage disequilibrium between a pair of single nucleotide polymorphisms). The square with "51" indicates D\' = 0.51](AIAN-20-5-g006){#F1}

Discussion {#sec1-4}
==========

This study was the first study from North India, which revealed that the C509T, G800A, and T869C polymorphisms of TGF-β1 gene and their haplotypes were significantly associated with increased risk of IS. Our findings confirm a significant association between TGF-β1 gene polymorphisms and risk of IS. A high degree of LD was observed between pairs of G800A and T869C SNPs in North Indian population. In this regard, the further haplotype analysis of the three polymorphisms was conducted, which is more useful for the identification of predisposing genes of complicated diseases.\[[@ref34]\] Our findings demonstrated that the haplotypes C509-A800-T869 (OR = 10.7; 95% CI 4.5--25.3) and T509-G800-C869 (OR = 2.09; 95% CI 1.47--2.99) were associated with a higher risk of developing IS. Our findings imply that these haplotypes may be a risk factor in independently modifying individual susceptibility to the development of IS in North Indian population.

Only a few studies are available which investigated the relationship between human TGF-β1 SNPs and stroke.\[[@ref11][@ref18][@ref19][@ref20]\] The case--control study published by Xie *et al*. did not show any significant association between TGF-β1 G800A gene polymorphism and risk of Cerebral Infarction in Chinese Population.\[[@ref24]\] A meta-analysis of six studies conducted by Peng *et al*. involving 1701 cases did not show any significant association between TGF-β1 T869C polymorphism and risk of IS under all genetic models.\[[@ref30]\] However, this meta-analysis was conducted only in a Chinese population with a significant amount of heterogeneity present between the studies including different study designs. The observed differences in the results may be due to different dietary and lifestyle choices of Chinese and Indian populations.\[[@ref35][@ref36]\] Therefore, the results of this meta-analysis cannot be used to draw any profound evidences in the North Indian population. The results in the present study provide more convincing evidence of the association between TGF-β1 gene polymorphisms and risk of IS after adjusting the confounding variables, including hypertension, alcohol, diabetes, dyslipidemia, smoking, family history of stroke, sedentary lifestyle, and low socioeconomic status. Genotype distribution in all the controls did not deviate from HWE, reassuring the representation of control samples. In addition, we conducted an adjusted analysis for multiple comparisons under all genetic models.

IS a clinically heterogeneous disorder encompassing stroke\'s attributable to various etiologies and thus, we investigated the heterogeneous genetic effect of TGF-β1 on IS subtypes based on TOAST classification. The effect of these polymorphisms was mainly confined to LVD and SVD among IS subtypes. Although the pathogenesis of SVD and LVD is not clearly understood, thrombosis is a major contributor to SVD. TGF-β1 is an anti-inflammatory cytokine that is believed to play a key role in thrombosis and therefore, it might be related to thrombotic occlusion of small vessels by regulating inflammatory process. Several studies have confirmed that the involvement of TGF-β1 in atherosclerosis plays a key role by inhibiting inflammation and increasing atherosclerotic plaque stabilization, and hence appears to be anti-atherogenic. The potential explanation for these inconsistent findings is that dissimilarities in the prevalence of conventional risk factors for IS, including coronary artery disease, arterial hypertension, hypercholesterolemia, and cigarette smoking may have also contributed to the divergent results between the study populations and other reasons include the small sample size (164 cases and 167 controls) in Peng *et al*. study.

However, recent studies demonstrated that TGF-β1 is associated with vascular stenosis and thrombogenesis by promoting fibrosis and inhibiting endothelial regeneration and hence is a pro-atherogenic factor.

However, there were a few limitations in our study. First, the study was conducted in a single hospital, and the participants might not have been the representatives from other areas. Therefore, further large sample size and multicentric studies are needed to confirm our findings. Second, no levels of TGF-β were determined; therefore, we were unable to elucidate the effect of the polymorphism on TGF-β levels. Third, more than 147 SNP sites have been known; but in our study, we focused on three SNPs of TGF-β1 gene which might infer the effect of other SNPs on phenotypes which further needs to be studied. Despite these limitations, our study provides strong evidence for the association between TGF-β1 gene polymorphisms and risk of IS.

Conclusion {#sec1-5}
==========

Our results suggest that TGF-β1 polymorphisms and their haplotypes are significantly associated with the risk of IS in North Indian population.
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